Technology
Health
Medical

Cytosorbents

$7.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-5.63%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cytosorbents and other stocks, options, ETFs, and crypto commission-free!

About

CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. Read More The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Employees
125
Headquarters
Monmouth Junction, New Jersey
Founded
2002
Market Cap
239.89M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
232.47K
High Today
$8.02
Low Today
$7.52
Open Price
$7.93
Volume
66.71K
52 Week High
$14.95
52 Week Low
$6.67

Collections

Technology
Health
Medical
US
North America

News

The Motley FoolMar 7

Cytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript

Cytosorbents Corp (NASDAQ:CTSO) Q4 2018 Earnings Conference Call , 4:45 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the CytoSorbents 2018 Financial and Operating Results Conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request. At this time, I'd like...

22
Seeking AlphaMar 7

Cytosorbents misses by $0.04, revenue in-line - Cytosorbents Corp (NASDAQ:CTSO)

41
Markets InsiderMar 7

CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018

MONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record total revenue, CytoSorb® sales, and product gross margins in 2018. 2018 Financial Highlights: Full year 2018 total revenue was $22.5 million , including both product sales and grant income, a 49% increase fro...

8

Earnings

-$0.19
-$0.14
-$0.09
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.